Could a weekly shot help people with type 1 diabetes lose weight and control blood sugar?
NCT ID NCT05537233
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a weekly injection of semaglutide (a drug used for type 2 diabetes and weight loss) in 115 adults with type 1 diabetes and obesity who already use an automated insulin pump. The goal was to see if adding semaglutide helps improve blood sugar levels, reduce hypoglycemia, and lower body weight. Participants received either semaglutide or a placebo for 26 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- semaglutide
- What this could lead to
- If successful, this could offer a new way to improve blood sugar control and reduce weight in people with type 1 diabetes who are overweight.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with only 115 participants. Results may not apply to everyone, and semaglutide can cause side effects like nausea or vomiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
115 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
Aug 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: For an eligible subject, all inclusion criteria must be answered "yes" 1. Age ≥18 and ≤ 65 years 2. Patients with clinical diagnosis of T1D diagnosed for at least 12 months 3. Patient is on FDA- approved hybrid closed-loop system for ≥ 3 months 4. Willing to use once weekly semaglutide 5. Willing to share devices (HCL system) data uploads 6. HbA1c \>7.0% and \<10.0% 7. Body mass index ≥30 kg/m2 8. Has current glucagon product to treat severe hypoglycemia 9. Has current ketone meters to check ketones 10. Ability to provide informed consent before any trial-related activities Exclusion Criteria: 1. Age \<18 years and \>65 years 2. HbA1c ≤7.0 % or ≥ 10.0% at screening 3. Less than 12 months of insulin treatment 4. Use of unapproved insulin for HCL system. E.g. use of Fiasp in the Tandem Control-IQ system 5. Not willing to share the devices (HCL system) data uploads 6. Non compatible devices (e.g. pump, CGM or smart phones) for data transfer 7. Current use of multiple daily injection or inhaled insulin (Afrezza) 8. Patients with T1D using any glucose lowering medications other than insulin at the time of screening 9. Pregnancy, breast feeding, and positive pregnancy test during screening 10. Women of childbearing age wanting to become pregnant 11. Unwilling to use acceptable contraceptive methods (for both men and women) during the trial period 12. Current use (≥ 2 weeks of continuous use) of any steroidal medication, or anticipated long-term steroidal treatment (\>4 weeks continuously), during the study period 13. Use of GLP-1RA or weight loss medications in the past 3 month 14. Clinical diagnosis/history of gastroparesis or gastric motility disorders 15. Serum triglycerides \>500 mg/dL 16. Planning for bariatric surgery during the study period 17. eGFR below 45 ml/min/1.73 m\^2 using CKD-EPI formula 18. History of severe hypoglycemia in the previous 3 months 19. History of diabetic ketoacidosis requiring hospitalization in the past 3 months 20. History of allergy to any form of insulin, GLP-1RA or its excipients 21. History of any form of pancreatitis 22. History of stroke, myocardial infarction in the past 3 months 23. History of congestive heart failure class III or IV 24. History of acute or chronic liver disease 25. History of malignancy requiring chemotherapy, surgery or radiation in previous 5 years 26. Personal or family history of multiple endocrine neoplasia type 2 (MEN-2) or familial thyroid carcinoma or non-familial medullary thyroid carcinoma 27. Have a pacemaker, metal implants, or aneurysm clips or weigh \>330 lbs (exclusion only if doing MRI) 28. Use of investigational drugs within 5 half-lives prior to screening 29. Participation to other intervention trials during the study period 30. Any comorbidities or medical conditions such as severe psychiatric disorder that make a person unfit for the study at the discretion of the investigators
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barbara Davis Center for Diabetes
Aurora, Colorado, 80045, United States
-
Harold Schnitzer Diabetes Health Center
Portland, Oregon, 97239, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Iowa Diabetes Research Center
West Des Moines, Iowa, 50265, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin sensors replace finger pricks for diabetes care in kenya?
- Which exercise dose best helps kids with metabolic syndrome?
- Custom knee guides put to the test in obese patients
- A pill for obesity? early human trial puts MDR-001 to the test
- Can a weekly shot help people who still struggle with weight after bariatric surgery?
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?